uniQure (NASDAQ:QURE) Director Jack Kaye Sells 21,167 Shares

uniQure N.V. (NASDAQ:QURE) Director Jack Kaye sold 21,167 shares of the business’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $46.44, for a total transaction of $982,995.48. Following the transaction, the director directly owned 25,996 shares of the company’s stock, valued at approximately $1,207,254.24. This trade represents a 44.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jack Kaye also recently made the following trade(s):

• On Wednesday, June 17th, Jack Kaye sold 5,295 shares of uniQure stock. The stock was sold at an average price of $42.57, for a total transaction of $225,408.15.
• On Thursday, June 11th, Jack Kaye sold 1,993 shares of uniQure stock. The shares were sold at an average price of $27.06, for a total transaction of $53,930.58.
• On Wednesday, June 3rd, Jack Kaye sold 2,645 shares of uniQure stock. The shares were sold at an average price of $30.01, for a total transaction of $79,376.45.

uniQure Price Performance

NASDAQ QURE opened at $41.81 on Friday. uniQure N.V. has a 52 week low of $8.73 and a 52 week high of $71.50. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The stock has a market cap of $2.64 billion, a price-to-earnings ratio of -12.01 and a beta of 0.90. The company has a 50-day moving average price of $30.05 and a two-hundred day moving average price of $23.73.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The business had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. Analysts forecast that uniQure N.V. will post -3.63 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on QURE. Cantor Fitzgerald raised uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target on the stock in a report on Wednesday, June 17th. Chardan Capital upped their price objective on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Leerink Partners increased their target price on shares of uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a research report on Thursday, June 18th. HC Wainwright raised their target price on shares of uniQure from $50.00 to $80.00 and gave the company a “buy” rating in a research note on Monday. Finally, Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Twelve research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, uniQure currently has an average rating of “Moderate Buy” and a consensus target price of $64.17.

Hedge Funds Weigh In On uniQure

Large investors have recently made changes to their positions in the business. Woodline Partners LP raised its holdings in shares of uniQure by 25.0% in the 1st quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after purchasing an additional 35,175 shares in the last quarter. Legal & General Group Plc bought a new stake in uniQure during the second quarter worth approximately $497,000. Marshall Wace LLP grew its position in uniQure by 276.5% in the second quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company’s stock worth $3,108,000 after buying an additional 163,749 shares during the last quarter. California State Teachers Retirement System acquired a new position in uniQure in the second quarter worth approximately $540,000. Finally, Ameriprise Financial Inc. increased its holdings in shares of uniQure by 38.6% in the second quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock valued at $10,622,000 after buying an additional 212,218 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $80 price target while raising multiple earnings estimates for uniQure, including near- and longer-term forecasts. The improved outlook suggests analysts see stronger future profitability than before. uniQure analyst update
• Positive Sentiment: Recent technical coverage highlighted that QURE is trading above a golden cross, which traders often view as a bullish momentum signal and a possible support level. Zacks golden cross article
• Neutral Sentiment: Media attention also included a comparison piece on uniQure versus Viridian Therapeutics and a short-squeeze watchlist mention, which may be adding trading interest but does not directly change fundamentals. AAII comparison article
• Negative Sentiment: Director Jack Kaye and insider Walid Abi-Saab both sold shares in recent SEC filings. Although the trades were made under pre-arranged 10b5-1 plans, insider selling can still weigh on sentiment. Jack Kaye SEC filing Walid Abi-Saab SEC filing

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.